Meraki Acquisition One Inc (MRKI.P) 시세

Nothing goes straight up.
It’s an up n down process.
As long as the trend is your is your friend, ride it to the end.
RSI is good, not overbought.
DMAs all trending in the right direction on the yr/day chart.
BB is moving upward, & as long as it is keeping up with

TCTM.....................MULN................................https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=2&dy=12&id=p84071410134

The SGTM-VRM offers innovative solutions for managing diseases, reducing the reliance on chemical interventions. Moreover, their formulations promote the biological fixation of essential nutrients, enhancing soil remediation and supporting large-scale agriculture.

You need therapy....master555...you are a joker...go take your medication...loser

IONQ could go green by EOD. impressive considering all the news on ai.

MSG, did you see the dramatic increase of the bid?

Watch FNVWF, $0.05. It'll go to dollars with $1 Billion Reverse Merger with an EV truck company coming soon!

FNVWF, $0.05, filing for $1 Billion Reverse Merger :

https://www.otcmarkets.com/filing/html?id=18092314&guid=2_0-kee5FMdqJth

With just 4.3 M O/S,

Thanks..Again..Chartmaster..for..the..News..Update

This goes north 2025

Coming in here in a sec, putting another 2K in on the 30th!

John Thune, Man on a Mission

Any doubt he would work with Trump is gone now.

by James Fite | Jan 27, 2025


Senate Majority Leader John Thune (R-SD) and President Donald Trump have a rocky past. But the upper-chamber lawmaker has clearly put all tha

John Thune, Man on a Mission

Any doubt he would work with Trump is gone now.

by James Fite | Jan 27, 2025


Senate Majority Leader John Thune (R-SD) and President Donald Trump have a rocky past. But the upper-chamber lawmaker has clearly put all tha

out

There was nothing in the recent technical action to cause 'Zalmy' to use that as a basis for this recommendation. This suggests that he has somehow gotten knowledge of the results of the new recovery scheme at the Bishop Mill, and the results are outstanding. PR soon, I'm thinking.

Anyone have access to the document that can share some of the details?

how many times you will bore us with the same topic..

The answer is nobody knows at this time... If you are here asking this question just to confuse the newbies, we can ask the admins to create a new board for that purpose

~ Well, All of youzzz "COOP" peeps ... Have A Nice Day / week / etc. ~

ol' cactus won't argus, debate, be told what to do (LOL), ... suggest or tell anyone to buy, sell, or hold "anything" ... etc. etc. ... cactus will remove my own earned profit at will (LOL) ... I simply look for an

125 million shares already, 91 million on the buy side and the price goes nowhere. For weeks we have watched this same activity you all have believed you can flip this. That regulation A offering price will likely get modified and when it does...🫣

Kraig Biocraft Laboratories achieves Knock-in Knock-out Success to create nearly Pure Spider Silk
ANN ARBOR, Mich., April 16, 2020 (GLOBE NEWSWIRE)

This new technology has applications and implications far beyond material performance. The Company is now well underway, and rapid

Not quite the same thing. SEC Q and K reports are NOT paid promotions.

Well 90% of submissions were approved last year yet you focus a lot on the 10% not so it doesn't seem wrong to also consider that not all submissions require a first clock stop despite it being "almost always necessary".

Buying opportunity. No wonder why you’re down if you don’t realize it. JMO.

Remember Tomorrow

https://www.biospace.com/rennova-health-inc-ceo-provides-january-2024-message-to-shareholders

Notice this 2024 letter to shareholders focused mainly on the two assets that now belong to FOXO. So, where does that leave us. There are many links throughout the years Seamus telling shareh

Actually, I did not follow his advice.

Again, it's up to an individual investor and their OWN PERSONAL FINANCIAL SITUATION.

I don't know how you overlooked that VERY important piece of information.